/PRTA
PRTA Stock - Prothena Corporation plc
Healthcare|BiotechnologyNASDAQ
$9.21-1.81%
$0.17 (-1.81%) • Dec 19
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.41
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+182.3%upside
Target: $26.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for PRTA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.12 – $9.30
TARGET (TP)$26.00
STOP LOSS$8.47
RISK/REWARD1:22.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.10
52W High$16.66
52W Low$4.32
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $135.16M | $91.37M | $53.91M | $200.58M | $853,000 |
| Gross Profit | $135.16M | $91.37M | $53.91M | $200.58M | $-74,031,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | -8678.9% |
| Operating Income | $-154,561,000 | $-191,036,000 | $-131,557,000 | $71.97M | $-112,734,000 |
| Net Income | $-122,310,000 | $-147,028,000 | $-116,949,000 | $66.97M | $-111,144,000 |
| Net Margin | -90.5% | -160.9% | -217.0% | 33.4% | -13029.8% |
| EPS | $-2.27 | $-2.76 | $-2.47 | $1.51 | $-2.78 |
Company Overview
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
50%
Hold / Neutral
3
38%
Sell / Underperform
1
13%
Analyst Consensus🟡 Mixed
4 Bullish4 Neutral/Bearish
Price Targets
$47
Average Target
↑ 414.4% Upside
Now
$4
Low
$47
Average
$94
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 28th 2025 | BofA Securities | Downgrade | Underperform | $4 |
| May 27th 2025 | Oppenheimer | Downgrade | Perform | - |
| May 27th 2025 | Jefferies | Downgrade | Hold | $6 |
| May 27th 2025 | Cantor Fitzgerald | Downgrade | Neutral | - |
| December 20th 2024 | Chardan Capital Markets | Initiation | Buy | $40 |
| January 30th 2024 | BofA Securities | Downgrade | Neutral | $38← $68 |
| December 12th 2023 | Deutsche Bank | Initiation | Buy | $62 |
| April 24th 2023 | SVB Securities | Initiation | Outperform | $80 |
| January 27th 2023 | Piper Sandler | Initiation | Overweight | $94 |
| November 4th 2022 | RBC Capital Mkts | Downgrade | Sector Perform | $55← $52 |
| September 28th 2022 | BofA Securities | Upgrade | Buy | - |
Earnings History & Surprises
PRTABeat Rate
33%
Last 18 quarters
Avg Surprise
+5.9%
EPS vs Estimate
Beats / Misses
6/12
Last 12 quarters
Latest EPS
$-0.67
Q4 2025
EPS Surprise History
Q1 24
-2.4%
$-1.26vs$-1.23
Q2 24
-10.7%
$-1.34vs$-1.21
Q3 24
+216.2%
$1.22vs$-1.05
Q4 24
+6.8%
$-1.10vs$-1.18
Q1 25
-5.9%
$-1.08vs$-1.02
Q2 25
-21.7%
$-1.12vs$-0.92
Q3 25
-67.6%
$-1.86vs$-1.11
Q4 25
-11.7%
$-0.67vs$-0.60
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 19, 2026 | $-0.45 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.60 | $-0.67 | -11.7% | ✗ MISS |
Q3 2025 | Aug 4, 2025 | $-1.11 | $-1.86 | -67.6% | ✗ MISS |
Q2 2025 | May 8, 2025 | $-0.92 | $-1.12 | -21.7% | ✗ MISS |
Q1 2025 | Feb 20, 2025 | $-1.02 | $-1.08 | -5.9% | ✗ MISS |
Q4 2024 | Nov 12, 2024 | $-1.18 | $-1.10 | +6.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-1.05 | $1.22 | +216.2% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-1.21 | $-1.34 | -10.7% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-1.23 | $-1.26 | -2.4% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.32 | $0.38 | +218.8% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.92 | $-1.03 | -12.0% | ✗ MISS |
Q2 2023 | May 4, 2023 | $-0.83 | $-0.89 | -7.2% | ✗ MISS |
Q1 2023 | Feb 23, 2023 | $-0.47 | $0.12 | +125.5% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.31 | $-0.97 | -212.9% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.51 | $-0.88 | -72.5% | ✗ MISS |
Q2 2022 | May 5, 2022 | $-0.85 | $-0.78 | +8.2% | ✓ BEAT |
Q1 2022 | Feb 17, 2022 | $-0.74 | $-0.71 | +4.1% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $2.28 | $2.13 | -6.6% | ✗ MISS |
Q3 2021 | Aug 5, 2021 | $1.00 | $0.58 | -42.0% | ✗ MISS |
Latest News
Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $19
📈 PositiveBenzinga•Dec 1, 2025, 01:17 PM
Prothena Data From TDP-43 CYTOPE Program Demonstrates CYTOPE Technology's Potential To Deliver Large Molecules Into Cells
📈 PositiveBenzinga•Nov 19, 2025, 09:09 PM
Prothena Presents Phase 2 Clinical Study Data For Coramitug For Treatment Of ATTR Amyloidosis With Cardiomyopathy American Heart Association's Circulation Journal
📈 PositiveBenzinga•Nov 11, 2025, 02:03 PM
HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $30
📈 PositiveBenzinga•Nov 7, 2025, 07:50 PM
RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $11
➖ NeutralBenzinga•Nov 7, 2025, 07:21 PM
Prothena Corp Q3 Adj. EPS $(0.68) Beats $(0.69) Estimate, Sales $2.415M Miss $6.639M Estimate
📉 NegativeBenzinga•Nov 6, 2025, 09:17 PM
Piper Sandler Maintains Overweight on Prothena Corp, Raises Price Target to $36
📈 PositiveBenzinga•Oct 28, 2025, 11:58 AM
HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $20
📈 PositiveBenzinga•Oct 7, 2025, 02:12 PM
Prothena's Partner Bristol Myers Squibb Receives Fast Track Designation From The FDA For BMS-986446 For The Treatment of Alzheimer's Disease
📈 PositiveBenzinga•Oct 1, 2025, 09:12 PM•Also:
JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $11
➖ NeutralBenzinga•Sep 2, 2025, 11:41 AM
Piper Sandler Maintains Overweight on Prothena Corp, Lowers Price Target to $15
➖ NeutralBenzinga•Aug 28, 2025, 02:27 PM
Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target
📈 PositiveBenzinga•Aug 28, 2025, 12:01 PM
PRTA stock has given up its prior loss. Prothena shares were trading lower after the company reported Phase 1 results for PRX012.
➖ NeutralBenzinga•Aug 27, 2025, 09:31 PM
Prothena shares are trading lower after the company reported Phase 1 results for PRX012.
📉 NegativeBenzinga•Aug 27, 2025, 08:28 PM
Prothena Reports Phase 1 Results For PRX012 In Alzheimer's; Explores Partnerships To Advance PRX012 And TfR-Linked Preclinical Program
📈 PositiveBenzinga•Aug 27, 2025, 08:15 PM
Prothena jumps as partner Roche to advance Parkinson's drug into late-stage studies
📈 PositiveSeeking Alpha•Jun 16, 2025, 12:56 PM•Also:
Prothena hits 52-week low amid downgrades after late-stage trial setback
📉 NegativeSeeking Alpha•May 27, 2025, 04:04 PM
Biggest stock movers Tuesday: INFA, PRTA, and more
➖ NeutralSeeking Alpha•May 27, 2025, 09:00 AM•Also: , ,
Prothena to evaluate options after phase 3 birtamimab failure; shares plunge
📉 NegativeSeeking Alpha•May 23, 2025, 09:29 PM
Prothena GAAP EPS of -$1.12 misses by $0.10, revenue of $2.8M misses by $5.38M
📉 NegativeSeeking Alpha•May 8, 2025, 08:53 PM
Frequently Asked Questions about PRTA
What is PRTA's current stock price?
Prothena Corporation plc (PRTA) is currently trading at $9.21 per share. The stock has moved -1.81% today.
What is the analyst price target for PRTA?
The average analyst price target for PRTA is $26.00, based on 1 analyst.
What sector is Prothena Corporation plc in?
Prothena Corporation plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is PRTA's market cap?
Prothena Corporation plc has a market capitalization of $0.50 billion, making it a small-cap company.
Does PRTA pay dividends?
No, Prothena Corporation plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBCYC
Bicycle Therapeutics plc
$6.87
Mkt Cap: $0.5B
CRVS
Corvus Pharmaceuticals, Inc.
$7.49
Mkt Cap: $0.6B
FDMT
4D Molecular Therapeutics, Inc.
$8.68
Mkt Cap: $0.4B
GOSS
Gossamer Bio, Inc.
$3.44
Mkt Cap: $0.8B
KALV
KalVista Pharmaceuticals, Inc.
$15.23
Mkt Cap: $0.8B
NMRA
Neumora Therapeutics, Inc. Common Stock
$1.75
Mkt Cap: $0.3B
OLMA
Olema Pharmaceuticals, Inc.
$27.93
Mkt Cap: $1.9B
RIGL
Rigel Pharmaceuticals, Inc.
$41.59
Mkt Cap: $0.7B
VSTM
Verastem, Inc.
$7.76
Mkt Cap: $0.5B
VTYX
Ventyx Biosciences, Inc.
$8.74
Mkt Cap: $0.6B
Explore stocks similar to PRTA for comparison